Pfizer's financial results have been subpar in recent years. The company's newer products are starting to come into their own. The drugmaker's pipeline could lead to even more important brand-new ...
GLP-1 drugs have seen strong consumer demand. Eli Lilly's industry-leading GLP-1 drugs Mounjaro and Zepbound, for example, saw revenue growth of 99% and 175%, respectively, in 2025. The flameout of ...
The Motley Fool on MSN
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know.
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.
Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.
Pfizer stock (PFE) looks undervalued with a 6.7% dividend, easing LOE headwinds, and strong pipeline execution. Read the ...
PFE has been testing $26 since February but has breached another key level Pfizer Inc (NYSE:PFE) stock is down 1.1% to trade at $26.03 at last check. PFE is reversing premarket lead despite the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results